glp1versus

Bydureon BCise vs Foundayo

exenatide extended-release (GLP-1 receptor agonist) vs orforglipron (GLP-1 receptor agonist (oral small-molecule)) — a complete side-by-side comparison.

AstraZenecaEli Lilly and Company

Bydureon BCise weight loss

2.3%

Foundayo weight loss

12.4%

Bydureon BCise dosing

Once weekly

Foundayo dosing

Once daily

Reviewed by Dr. Elena Vance, DOLast reviewed 7 sources cited

Quick Summary

Bydureon BCise (exenatide) and Foundayo (orforglipron) are both glp-1 receptor agonists. In clinical trials, Foundayo showed greater weight loss (12.4% vs 2.3%).

See the comparison table below for detailed side-by-side data.

Bydureon BCise vs Foundayo: Full Comparison

FeatureBydureon BCise(exenatide extended-release)Foundayo(orforglipron)
Active Ingredientexenatideorforglipron
Drug ClassGLP-1 receptor agonistGLP-1 receptor agonist (oral small-molecule)
ManufacturerAstraZenecaEli Lilly and Company
FDA Approved2012-01-272026-04-01
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
Routesubcutaneous injectionoral
FrequencyOnce weeklyOnce daily
Starting Dose2 mg weekly3 mg once daily
Maintenance Dose2 mg weekly12 mg or 36 mg once daily
Max Dose2 mg weekly36 mg once daily
Weight Loss (%)2.3%12.4%
A1C Reduction1.3%N/A (not indicated for diabetes)
Key TrialDURATION-1 (30 weeks)ATTAIN-1 (72 weeks)
List Price$800-$950/monthPricing announced at U.S. launch (April 2026); confirm with LillyDirect
With Insurance$25-$100/month (varies by plan)Formulary coverage evolving; many commercial plans expected to require prior authorization
Savings CardLimited savings programs availableEli Lilly savings program details emerging via LillyDirect

Side Effects: Bydureon BCise vs Foundayo

Side EffectBydureon BCiseFoundayo
Nausea11%21-27%
Diarrhea9%15-20%
Injection site nodule10-17%Not reported
Headache8%5-8%
Vomiting4%10-16%
Constipation6%8-14%
Pancreatitis (rare)<1%<0.5%
Indigestion/dyspepsiaNot reported6-10%
Abdominal painNot reported5-9%
FatigueNot reported4-7%
Hair lossNot reported3-5%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Bydureon BCise vs OzempicFoundayo vs OzempicBydureon BCise vs WegovyFoundayo vs WegovyBydureon BCise vs MounjaroFoundayo vs MounjaroBydureon BCise vs ZepboundFoundayo vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Bydureon BCise FDA Drugs@FDA approval record — FDA
  2. Foundayo FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. DURATION-1 clinical trial record — ClinicalTrials.gov
  2. ATTAIN-1 clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. Drucker DJ et al. Exenatide once weekly versus twice daily for treatment of type 2 diabetes (DURATION-1). Lancet 2008;372:1240-1250 — The Lancet

Manufacturer Information

  1. Bydureon BCise patient website (AstraZeneca) — AstraZeneca

Reference Entries

  1. Exenatide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.